Skip to main content

Rhinovirus

1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
1 program
1
APL-10456Phase 11 trial
Active Trials
NCT07399132Recruiting144Est. Oct 2027
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
2 programs
BTA798PHASE_21 trial
VapendavirPHASE_2Small Molecule1 trial
Active Trials
NCT01175226Completed300Est. Mar 2012
NCT03024177Withdrawn0
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Nasal Swab Healthy SurveillanceN/A1 trial
Active Trials
NCT07342582Not Yet Recruiting670Est. May 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
VaxartBTA798
Apollo TherapeuticsAPL-10456
Allergy TherapeuticsNasal Swab Healthy Surveillance

Clinical Trials (4)

Total enrollment: 1,114 patients across 4 trials

NCT03024177VaxartVapendavir

A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

0
Phase 2Withdrawn
NCT01175226VaxartBTA798

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Start: Aug 2010Est. completion: Mar 2012300 patients
Phase 2Completed
NCT07399132Apollo TherapeuticsAPL-10456

A Study of APL-10456-Vaccine

Start: Feb 2026Est. completion: Oct 2027144 patients
Phase 1Recruiting
NCT07342582Allergy TherapeuticsNasal Swab Healthy Surveillance

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

Start: May 2026Est. completion: May 2030670 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,114 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.